Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-23T14:01:45.244Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of systematic and narrative reviews: the example of the atypical antipsychotics

Published online by Cambridge University Press:  11 October 2011

Andrea Cipriani  and
John Geddes
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorials
Information
Epidemiology and Psychiatric Sciences , Volume 12 , Issue 3 , September 2003 , pp. 146 - 153
Copyright
Copyright © Cambridge University Press 2003

References

REFERENCES

Altman, D.G. & Bland, J.M. (1999). Statistics notes. Treatment allocation in controlled trials: why randomise? British Medical Journal 318, 1209.CrossRefGoogle ScholarPubMed
Altman, D.G. & Gardner, M.J. (1992). Confidence intervals for research findings. British Journal of Obstetrics and Gynaecology 99, 90–91.Google ScholarPubMed
Antman, E.M., Lau, J., Kupelnick, B., Mosteller, F. & Chalmers, T.C. (1992). A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. Journal of the American Medical Association 268, 240–248.CrossRefGoogle ScholarPubMed
Campbell, M., Young, P.I., Bateman, D.N., Smith, J.M. & Thomas, S.H. (1999). The use of atypical antipsychotics in the management of schizophrenia. British Journal of Clinical Pharmacology 41, 13–22.CrossRefGoogle Scholar
Carney, S.M. & Geddes, J.R. (2002). Systematic Reviews and Metaanalyses. Evidence in Mental Health Care. Brunner Routledge: Hove.Google Scholar
Cochrane Collaboration (1995). Cochrane Collaboration Handbook. Updated 1995. Cochrane Collaboration: Oxford.Google Scholar
Davis, J. & Chen, N. (2002). Clinical profile of an atypical antipsychotic: risperidone. Schizophrenia Bulletin 28, 43–61.Google ScholarPubMed
Detsky, A.S., Naylor, C.D., O'Rourke, K., McGeer, A.J. & L'Abbe, K.A. (1992). Incorporating variations in the quality of individual randomised trials into meta-analysis. Journal of Clinical Epidemiology 45, 255–265.CrossRefGoogle ScholarPubMed
Duggan, L., Fenton, M., Dardennes, R.M., El-Dosoky, A. & Indran, S. (2000). Olanzapine for schizophrenia. Cochrane Library Issue 4.CrossRefGoogle Scholar
Egger, M. & Smith, G.D. (1998). Bias in location and selection of studies. British Medical Journal 316, 61–66.CrossRefGoogle ScholarPubMed
Freemantle, N. (2001). Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? British Medical Journal 322, 989–991.CrossRefGoogle ScholarPubMed
Geddes, J.R., Wilczynski, N., Reynolds, S., Szatmari, P. & Streiner, D.L. (1999). Evidence-based mental health the first year. EvidenceBased Mental Health 2, 3–5.Google Scholar
Geddes, J.R., Freemantle, N., Harrison, P.J. & Bebbington, P.E. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic review and meta-regression analysis. British Medical Journal 321, 1371–1376.CrossRefGoogle Scholar
Gilbody, S.M. & Song, F. (2000). Publication bias and the integrity of psychiatry research. Psychological Medicine 30, 253–258.CrossRefGoogle ScholarPubMed
Hopayian, K. (2001). The need for caution in interpreting high quality systematic reviews. British Medical Journal 323, 681–684.CrossRefGoogle ScholarPubMed
Irwig, L., Tosteson, A.N., Gatsonis, C., Lau, J., Colditz, G., Chalmers, T.C. & Mosteller, F. (1994). Guidelines for meta-analyses evaluating diagnostic tests. Annals of Internal Medicine 120, 667–676.CrossRefGoogle ScholarPubMed
Johnson, A.L. (1983). Clinical trials in psychiatry. Psychological Medicine 13, 1–8.CrossRefGoogle ScholarPubMed
Kane, J. (1999). Olanzapine in the long-term treatment of schizophrenia. In Focus on Schizophrenia (ed. Tollefson, G.D.), British Journal of Psychiatry, Suppl. No. 37, vol. 174, pp. 26–29.Google Scholar
Leucht, S., Pitschel-Walz, G., Abraham, D. & Kissling, W. (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35, 51–68.CrossRefGoogle ScholarPubMed
Marder, S.R. (1999). Antipsychotic drugs and relapse prevention. Schizophrenia Research, Suppl. No. 1, vol. 35, pp. 87–92.CrossRefGoogle ScholarPubMed
Mulrow, C.D. (1987). The medical review article: state of the science. Annals of Internal Medicine 106, 485–488.CrossRefGoogle ScholarPubMed
Mulrow, C.D. (1994). Rationale for systematic reviews. British Medical Journal 309, 597–599.CrossRefGoogle ScholarPubMed
Mulrow, C.D., Williams, J.W. Jr., Gerety, M.B., Ramirez, G., Montiel, O.M. & Kerber, C. (1995). Case-finding instruments for depression in primary care settings. Annals of Internal Medicine 122, 913–921.CrossRefGoogle ScholarPubMed
Oxman, A.D. (1994). Systematic Reviews: Checklists for review articles. British Medical Journal 309, 648–651.CrossRefGoogle Scholar
Sackett, D.L. & Wennberg, J.E. (1997). Choosing the best research design for each question. British Medical Journal 315, 1636.Google ScholarPubMed
Stahl, S.M. (1999). Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. In What Makes an Antipsychotic Atypical? (ed. Stahl, S.M.), Journal of Clinical Psychiatry, Suppl. No.10, vol. 60, pp. 31–41.Google ScholarPubMed
Stephenson, C.M.E. & Pilowsky, L.S. (1999). Psychopharmacology of olanzapine. A review. In New Antipsychotics. Preclinical and Clinical Comparison (ed. Kerwin, R.), British Journal of Psychiatry, Suppl. No. 38, vol. 174, pp. 52–58.Google Scholar
Stewart, L.A. & Clarke, M.J. (1995). Practical methodology of metaanalyses (overviews) using updated individual patient data. Cochrane Working Group. Statistics in Medicine 14, 2057–2079.CrossRefGoogle ScholarPubMed
Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., Moher, D., Becker, B.J., Sipe, T.A. & Thacker, S.B. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. Journal of the American Medical Association 283, 2008–2012.CrossRefGoogle ScholarPubMed
Tandon, R., Milner, K. & Jibson, M.D. (1999). Antipsychotics from theory to practice: integrating clinical and basic data. In Advances in the Treatment of Psychosis in the Elderly (ed. Tariot, P.N.), Journal of Clinical Psychiatry, Suppl. No.8, vol. 60, pp. 21–28.Google ScholarPubMed
Thompson, S.G. (1994). Why sources of heterogeneity in meta-analysis should be investigated. British Medical Journal 309, 1351–1355.CrossRefGoogle ScholarPubMed
Thornley, B. & Adams, C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 317, 1181–1184.CrossRefGoogle ScholarPubMed
Tollefson, G.D. & Kuntz, A.J. (1999). Review of recent clinical studies with olanzapine. In Focus on Schizophrenia (ed. Tollefson, G.D.), British Journal of Psychiatry, Suppl. No. 37, vol. 174, pp. 30–35.Google Scholar
Waraich, P.S., Adams, C.E., Roque, M., Hamill, K.M. & Marti, J. (2002). Haloperidol dose for the acute phase of schizophrenia. Cochrane Library Issue 4.Google Scholar